SCHEMBL16355148

SCHEMBL16355148

O=C(Nc1ccccc1)c1cccc(-n2cnnn2)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.79
MEN1 O00255 7/20 0.79
SMN1; SMN2 Q16637 2/20 0.76
EPHX2 P34913 1/20 0.74
RAB9A P51151 3/20 0.73
USP2 O75604 2/20 0.69
NPC1 O15118 2/20 0.69
KDM4E B2RXH2 2/20 0.69
ALDH1A1 P00352 2/20 0.69
CYP1A2 P05177 1/20 0.69
CYP2D6 P10635 1/20 0.69
THRB P10828 1/20 0.69
HPGD P15428 1/20 0.69
MAPK1 P28482 1/20 0.69
HSD17B10 Q99714 1/20 0.69
JAK2 O60674 1/20 0.64
JAK1 P23458 1/20 0.64
TP53 P04637 2/20 0.63
L3MBTL1 Q9Y468 1/20 0.61
PPARG P37231 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14705833 0.88 MEN1 (1.00) KMT2AMEN1SMN1; SMN2EPHX2RAB9A
SCHEMBL16355155 0.88 KMT2A (0.78) KMT2AMEN1SMN1; SMN2EPHX2RAB9A
SCHEMBL14705700 0.85 MEN1 (0.73) KMT2AMEN1SMN1; SMN2EPHX2RAB9A
SCHEMBL31610095 0.83 MEN1 (0.64) KMT2AMEN1SMN1; SMN2EPHX2RAB9A
SCHEMBL27180217 0.81 LMNA (0.67) KMT2AMEN1SMN1; SMN2EPHX2RAB9A
SCHEMBL30926578 0.81 LMNA (0.67) KMT2AMEN1SMN1; SMN2EPHX2RAB9A
SCHEMBL939911 0.81 SMN1; SMN2 (0.71) KMT2AMEN1SMN1; SMN2EPHX2RAB9A
SCHEMBL31175292 0.81 SMN1; SMN2 (0.71) KMT2AMEN1SMN1; SMN2EPHX2RAB9A
SCHEMBL18762160 0.81 KMT2A (0.67) KMT2AMEN1SMN1; SMN2EPHX2RAB9A
SCHEMBL4583569 0.79 TP53 (0.70) KMT2AMEN1SMN1; SMN2EPHX2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790218-B2 Small molecule activators of calcium-activated chloride channels and methods of use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-10-17 US disclosed
US-9790218-B2 Small molecule activators of calcium-activated chloride channels and methods of use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-10-17 US disclosed
US-20140378510-A1 SMALL MOLECULE ACTIVATORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378510-A1 SMALL MOLECULE ACTIVATORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS AND METHODS OF USE CLCN2, KCNN1, KCNN2 KMT2A 4127/4885MEN1 1886/4885SMN1; SMN2 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.